Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer

• Published in: Hong Kong medical journal = Xianggang yi xue za zhi Vol. 24; no. 1; p. 56
• Main Authors: Yeo, W, Luk, M Y, Soong, I S, Yuen, T Ys, Ng, T Y, Mo, F Kf, Chan, K, Wong, S Y, Tsang, J, Leung, C, Suen, J Js, Ngan, R Kc
• Format: Journal Article
• Language: English; Chinese
• Published: China Hong Kong Academy of Medicine 01.02.2018
• Subjects: Adult; Aged; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Cancer therapies; Chemotherapy; Confidence intervals; Cytotoxicity; Endocrine therapy; Epidermal growth factor; Female; Hematology; Hong Kong - epidemiology; Humans; Maytansine - administration & dosage; Maytansine - adverse effects; Maytansine - analogs & derivatives; Metastasis; Middle Aged; Patients; Receptor, ErbB-2 - genetics; Retrospective Studies; Survival Analysis; Trastuzumab - administration & dosage; Trastuzumab - adverse effects; Hong Kong China; China; Breast neoplasms; Trastuzumab

The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has changed dramatically with the introduction and widespread use of HER2-targeted therapies. There is, however, relatively limited real-world information about the effectiveness and safety of trastuzumab emtans...